Redeye updates its estimates and valuation after Lagercrantz’s Q2 2025/2026 report. This quarter’s EBITA roughly matched our projection, while solid organic order intake growth provides cautious optimism for coming quarters despite a mixed picture across divisions. Lagercrantz describes its M&A pipeline as strong, boding well for acquired growth.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/